Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor
Abstract Ligand-activated signaling through the type 1 insulin-like growth factor receptor (IGF1R) is implicated in many physiological processes ranging from normal human growth to cancer proliferation and metastasis. IGF1R has also emerged as a target for receptor-mediated transcytosis, a transport...
Guardado en:
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/abc8b420f9a841a1ad3480689cc4f109 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:abc8b420f9a841a1ad3480689cc4f109 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:abc8b420f9a841a1ad3480689cc4f1092021-12-02T12:11:28ZDefining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor10.1038/s41598-021-83198-w2045-2322https://doaj.org/article/abc8b420f9a841a1ad3480689cc4f1092021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83198-whttps://doaj.org/toc/2045-2322Abstract Ligand-activated signaling through the type 1 insulin-like growth factor receptor (IGF1R) is implicated in many physiological processes ranging from normal human growth to cancer proliferation and metastasis. IGF1R has also emerged as a target for receptor-mediated transcytosis, a transport phenomenon that can be exploited to shuttle biotherapeutics across the blood–brain barrier (BBB). We employed differential hydrogen–deuterium exchange mass spectrometry (HDX-MS) and nuclear magnetic resonance (NMR) to characterize the interactions of the IGF1R ectodomain with a recently discovered BBB-crossing single-domain antibody (sdAb), VHH-IR5, in comparison with IGF-1 binding. HDX-MS confirmed that IGF-1 induced global conformational shifts in the L1/FnIII-1/-2 domains and α-CT helix of IGF1R. In contrast, the VHH-IR5 sdAb-mediated changes in conformational dynamics were limited to the α-CT helix and its immediate vicinity (L1 domain). High-resolution NMR spectroscopy titration data and linear peptide scanning demonstrated that VHH-IR5 has high-affinity binding interactions with a peptide sequence around the C-terminal region of the α-CT helix. Taken together, these results define a core linear epitope for VHH-IR5 within the α-CT helix, overlapping the IGF-1 binding site, and suggest a potential role for the α-CT helix in sdAb-mediated transcytosis.Joey SheffPing WangPing XuMelanie ArbourLuke MassonHenk van FaassenGreg HussackKristin KemmerichEric BrunetteDanica StanimirovicJennifer J. HillJohn KellyFeng NiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Joey Sheff Ping Wang Ping Xu Melanie Arbour Luke Masson Henk van Faassen Greg Hussack Kristin Kemmerich Eric Brunette Danica Stanimirovic Jennifer J. Hill John Kelly Feng Ni Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor |
description |
Abstract Ligand-activated signaling through the type 1 insulin-like growth factor receptor (IGF1R) is implicated in many physiological processes ranging from normal human growth to cancer proliferation and metastasis. IGF1R has also emerged as a target for receptor-mediated transcytosis, a transport phenomenon that can be exploited to shuttle biotherapeutics across the blood–brain barrier (BBB). We employed differential hydrogen–deuterium exchange mass spectrometry (HDX-MS) and nuclear magnetic resonance (NMR) to characterize the interactions of the IGF1R ectodomain with a recently discovered BBB-crossing single-domain antibody (sdAb), VHH-IR5, in comparison with IGF-1 binding. HDX-MS confirmed that IGF-1 induced global conformational shifts in the L1/FnIII-1/-2 domains and α-CT helix of IGF1R. In contrast, the VHH-IR5 sdAb-mediated changes in conformational dynamics were limited to the α-CT helix and its immediate vicinity (L1 domain). High-resolution NMR spectroscopy titration data and linear peptide scanning demonstrated that VHH-IR5 has high-affinity binding interactions with a peptide sequence around the C-terminal region of the α-CT helix. Taken together, these results define a core linear epitope for VHH-IR5 within the α-CT helix, overlapping the IGF-1 binding site, and suggest a potential role for the α-CT helix in sdAb-mediated transcytosis. |
format |
article |
author |
Joey Sheff Ping Wang Ping Xu Melanie Arbour Luke Masson Henk van Faassen Greg Hussack Kristin Kemmerich Eric Brunette Danica Stanimirovic Jennifer J. Hill John Kelly Feng Ni |
author_facet |
Joey Sheff Ping Wang Ping Xu Melanie Arbour Luke Masson Henk van Faassen Greg Hussack Kristin Kemmerich Eric Brunette Danica Stanimirovic Jennifer J. Hill John Kelly Feng Ni |
author_sort |
Joey Sheff |
title |
Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor |
title_short |
Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor |
title_full |
Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor |
title_fullStr |
Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor |
title_full_unstemmed |
Defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor |
title_sort |
defining the epitope of a blood–brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/abc8b420f9a841a1ad3480689cc4f109 |
work_keys_str_mv |
AT joeysheff definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor AT pingwang definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor AT pingxu definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor AT melaniearbour definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor AT lukemasson definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor AT henkvanfaassen definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor AT greghussack definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor AT kristinkemmerich definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor AT ericbrunette definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor AT danicastanimirovic definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor AT jenniferjhill definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor AT johnkelly definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor AT fengni definingtheepitopeofabloodbrainbarriercrossingsingledomainantibodyspecificforthetype1insulinlikegrowthfactorreceptor |
_version_ |
1718394649103564800 |